EverSource Wealth Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

EverSource Wealth Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-428	Closed	-$56.5K	–	4405
2025 Q1	$56.5K	Buy	428 +221	+107%	+$27.5K	﹤0.01%	1178
2024 Q4	$17.3K	Buy	207 +131	+172%	+$10.8K	﹤0.01%	1707
2024 Q3	$5.56K	Hold	76	–	–	﹤0.01%	2185
2024 Q2	$5.98K	Buy	76 +13	+21%	+$902	﹤0.01%	2149
2024 Q1	$4.53K	Buy	63 +1	+2%	+$69	﹤0.01%	2094
2023 Q4	$4.44K	Buy	62 +30	+94%	+$1.73K	﹤0.01%	1905
2023 Q3	$1.67K	Buy	32 +14	+78%	+$816	﹤0.01%	2069
2023 Q2	$1.14K	Buy	18 +8	+80%	+$499	﹤0.01%	2172
2023 Q1	$542	Buy	+10	New	+$483	﹤0.01%	2204

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

EverSource Wealth Advisors's ITCI Position: Q2 2025 in Review

EverSource Wealth Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 428 shares — an estimated $56.5K sold.

EverSource Wealth Advisors first reported a position in ITCI in Q1 2023 and held it in 9 quarters. The position peaked at $56.5K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

EverSource Wealth Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
EverSource Wealth Advisors sold 428 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $56.5K.
EverSource Wealth Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2023 and held it in 9 quarters.
EverSource Wealth Advisors's Intra-Cellular Therapies Inc. position peaked at $56.5K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on EverSource Wealth Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.